SAN DIEGO, Oct. 1 /PRNewswire-FirstCall/ -- Orexigen(R) Therapeutics, Inc. , a biopharmaceutical company focused on the treatment of obesity, today announced that the Company will be speaking at the Fourth Annual JMP Securities Healthcare Focus Conference. The details are as follows:
About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company’s lead investigational product, Contrave(R), has completed Phase 3 clinical trials and is on track for a regulatory submission with the FDA in the first half of 2010. The Company’s second product, Empatic(TM), has completed Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. Further information about the Company can be found at http://www.Orexigen.com.
SOURCE Orexigen Therapeutics, Inc.
CONTACT: Graham Cooper, Chief Financial Officer of Orexigen,
+1-858-875-8600, or Media, Lori Rosen of WeissComm Partners ,
+1-212-301-7173
Web site: http://www.Orexigen.com/
